NCT01664975 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 52
- group Id
- BG001
- value
- 51
- group Id
- BG002
- value
- 103
- units
- Participants
- groups
- description
- GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen GDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt(intravenously guttae),d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
- id
- BG000
- title
- GDPT Regimen
- description
- CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen CHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
- id
- BG001
- title
- CHOP Regimen
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 89
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 12
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 16
- upper Limit
- 69
- value
- 55
- group Id
- BG001
- lower Limit
- 15
- upper Limit
- 70
- value
- 51
- group Id
- BG002
- lower Limit
- 15
- upper Limit
- 70
- value
- 55
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 47
- title
- Female
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 56
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 52
- group Id
- BG001
- value
- 51
- group Id
- BG002
- value
- 103
- title
- China
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 52
- group Id
- BG001
- value
- 51
- group Id
- BG002
- value
- 103
- units
- Participants
- groups
- description
- GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen GDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt(intravenously guttae),d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
- id
- BG000
- title
- GDPT Regimen
- description
- CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen CHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
- id
- BG001
- title
- CHOP Regimen
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 89
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 12
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 16
- upper Limit
- 69
- value
- 55
- group Id
- BG001
- lower Limit
- 15
- upper Limit
- 70
- value
- 51
- group Id
- BG002
- lower Limit
- 15
- upper Limit
- 70
- value
- 55
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 47
- title
- Female
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 56
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 52
- group Id
- BG001
- value
- 51
- group Id
- BG002
- value
- 103
- title
- China
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle